GamEvac-Combi (Russian: ГамЭвак-Комби) is a heterologous VSV- and Ad5-vectored Ebola vaccine.
[1] GamEvac-Combi was developed by Gamaleya Research Institute of Epidemiology and Microbiology.
[2] The vaccine consists of live-attenuated recombinant vesicular stomatitis virus (VSV) and adenovirus serotype-5 (Ad5) expressing Ebola envelope glycoprotein.
[3] The vaccine is targeted against the Makona variant of Ebola that was circulating in West Africa during the 2013-2016 outbreak.
The emergency license was based on Phase I and II clinical data of safety and immunogenicity.